Is GlaxoSmithKline plc A Value Trap Or A Value Play?

Is it time to buy GlaxoSmithKline plc (LON:GSK) or should you avoid the company?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a rough year for us GlaxoSmithKline’s (LSE: GSK) shareholders. Year-to-date the company’s shares have fallen by around 6%, excluding dividends. That said, including dividends the company’s shares have drastically outperformed the FTSE 100. Glaxo’s shares have produced a total return of 0% since the beginning of 2015, compared to a return of -9% for the wider FTSE 100. 

However, after recent declines some City analysts and investors have started to question if Glaxo is a value trap. 

Value trap

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Value traps are difficult to spot. Finding them isn’t an exact science, and investors often get sucked into them when searching for bargains. 

Nevertheless, there are three key traits most value traps have in common and by avoiding companies that display these characteristics, you can increase your chances of avoiding such traps. 

Secular decline 

The first common feature of value traps is that of secular decline. More specifically, investors need to ask if the company in question’s revenue/profit or share price is falling due to cyclical factors, or if the company’s business model is under threat. 

A great example is that of Trinity Mirror, which has seen revenues slide over the past decade due to the secular decline of newspaper circulation and print advertising. Over the same period, the company’s share price has slumped 73%. 

In comparison, it’s pretty clear that Glaxo is suffering from neither cyclical nor structural factors. Healthcare isn’t a cyclical market and the demand for Glaxo’s vaccines and consumer healthcare products remains robust. 

Destroying value 

The second most common trait of value traps is the destruction of value. In other words, investors need to ask: did the company’s management destroy shareholder value by overpaying for acquisitions and mis-allocating capital? 

It looks as if Glaxo passes this test as well. The company has refrained from bidding for any smaller peers as valuations surge to eye-watering levels. Additionally, the group’s asset swap agreed with Novartis earlier this year seems to have unlocked a lot of value for investors. 

Cost of capital 

The third and final most common trait of value traps is a low return on capital invested. Put simply, if a company continuously earns a lower return on invested capital (equity and debt invested in the business) than the group’s cost of capital (debt interest costs), it deserves to trade below book value. 

According to my figures, Glaxo’s cost of capital is around 8.7%, based on 12-month figures. The same data also shows that Glaxo’s return on invested capital is 18.8%, more than double the group’s cost of capital. 

The bottom line

So overall, Glaxo passes each of my three value trap tests with flying colours. The company’s market isn’t in secular decline, management hasn’t wasted investors’ cash chasing expensive acquisitions, and the group’s return on capital is more than double its cost of capital. 

However, don’t buy any shares just yet

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Secure your FREE copy

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

Is £800 enough to start an ISA?

Is it worth bothering with an ISA with less than £1,000 to spare? This writer believes it may be --…

Read more »

Investing Articles

3 reasons Tesla stock may be a long-term bargain

This writer is keen to buy Tesla stock at the right price. He doesn't think it's there yet -- but…

Read more »

Investing Articles

Nvidia stock is a lot cheaper than before – or is it?

Nvidia stock has been caught in the whirlwind of market volatility. This writer has been waiting to buy, so might…

Read more »

Top Stocks

3 FTSE stocks Fools are eyeing up for choppy markets

A selection of companies listed on the UK stock market on the watchlists of four Foolish investors.

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

A £10,000 investment in Rolls-Royce shares last week is now worth this…

Harvey Jones says Rolls-Royce shares couldn't escape the volatility of recent weeks, but wonders if the recent dip is a…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Prediction: in 2 years these S&P 500 stocks will be much higher than they are today

These two S&P 500 stocks have been beaten down in recent weeks. But Edward Sheldon expects them to move much…

Read more »

Investing Articles

10% yields! Why a volatile stock market is great news for passive income investors

The recent stock market volatility has given passive income investors the chance to earn double-digit returns. But they still need…

Read more »

Close up of manual worker's equipment at construction site without people.
Investing Articles

Down 65% from its highs, this FTSE 250 stock is one to consider buying low

Shares in a strong FTSE 250 company going through a cyclical downturn have caught Stephen Wright’s attention as a potential…

Read more »